Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
SUIC Sino United Worldwide Consolidated Ltd
PSRU Valiant Eagle Inc
ON ON Semiconductor Corp
KHC Kraft Heinz Co
SUMO Sumo Logic Inc
TPGY+ TPG Pace Beneficial Finance Corp. *W EXP 10/09/2027
CSTA^ Constellation Acquisition Corp I
HFBL Home Federal Bancorp Inc of Louisiana
FSEA First Seacoast Bancorp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$115.42
Day's Change
-0.82 (-0.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
116.36
Day's Low
114.87
Volume
(Light)
Volume:
4,471,372

10-day average volume:
7,508,794
4,471,372

FINAL NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Clover Health Investments Corp. and Encourages Investors to Contact the Firm - CLOV, IPOC

11:45 pm ET April 6, 2021 (Globe Newswire) Print

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Clover Health Investments Corp. (NASDAQ: CLOV) ("Clover" or the "Company"), formerly known as Social Capital Hedosophia Holdings Corp. III (NYSE: IPOC), on behalf of investors who purchased shares of the Company's securities between October 6, 2020 and February 4, 2021, inclusive (the "Class Period").

Clover stockholders who purchased or acquired CLOV or IPOC securities securities prior to November 17, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 - 1585, or by email at skaskela@kaskelalaw.com or online at https://kaskelalaw.com/case/clover/, for additional information about this action and their legal rights and options.

As detailed in the complaint, on February 4, 2021, Hindenburg Research published a research report that revealed that Clover's flagship platform, Clover Assistant, was the subject of a U.S. Department of Justice ("DOJ") investigation for a variety of issues, including illegal kickbacks, marketing practices, and undisclosed related-party transactions. Hindenburg discovered that Clover's sales growth was not driven by technology, but by deceptive sales practices. Following this news, Clover common stock fell $1.72 per share, or over 12% in value, to close on February 4, 2021 at $12.23 per share.

The following day, Clover filed a Form 8-K disclosing that the SEC was conducting an "investigation and requesting document and data preservation for the period from January 1, 2020, to the present, relating to certain matters that are referenced in the [Hindenburg Research report]."

Clover stockholders are encouraged to contact Kaskela Law LLC for additional information about this action. Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

D. Seamus Kaskela, Esq.

KASKELA LAW LLC

18 Campus Boulevard, Suite 100

Newtown Square, PA 19073

(484) 258 - 1585

(888) 715 - 1740

www.kaskelalaw.com

skaskela@kaskelalaw.com

This notice may constitute attorney advertising in certain jurisdictions.

https://ml.globenewswire.com/media/46a37084-e0b3-48fa-b515-02e82ff9d30a/small/kaskela-law-logo1-jpg.jpg

https://ml.globenewswire.com/media/46a37084-e0b3-48fa-b515-02e82ff9d30a/small/kaskela-law-logo1-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.